Previous Article | Next Article 
Infection and Immunity, February 2001, p. 906-911, Vol. 69, No. 2
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.2.906-911.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Migration-Inhibitory Factor Gene-Deficient Mice Are Susceptible
to Cutaneous Leishmania major Infection
Abhay R.
Satoskar,*
Marcelo
Bozza,
Miriam
Rodriguez
Sosa,
Guoshing
Lin, and
John R.
David
Department of Immunology and Infectious
Diseases, Harvard School of Public Health, Boston, Masschusetts
02115
Received 9 May 2000/Returned for modification 10 July 2000/Accepted 10 November 2000
 |
ABSTRACT |
To determine the role of endogenous migration-inhibitory factor
(MIF) in the development of protective immunity against cutaneous leishmaniasis, we analyzed the course of cutaneous Leishmania major infection in MIF gene-deficient mice (MIF
/
)
and wild-type (MIF+/+) mice. Following cutaneous L. major infection, MIF
/
mice were susceptible to
disease and developed significantly larger lesions and greater parasite
burdens than MIF+/+ mice. Interestingly, antigen-stimulated
lymph node cells from MIF
/
mice produced more
interleukin-4 (IL-4) and gamma interferon (IFN-
) than those from
MIF+/+ mice, although the differences were statistically
not significant. IFN-
-activated resting peritoneal macrophages from
MIF
/
mice showed impaired macrophage leishmanicidal
activity and produced significantly lower levels of nitric oxide and
superoxide in vitro. The macrophages from MIF
/
mice,
however, produced much more IL-6 than macrophages from wild-type mice.
These findings demonstrate that endogenous MIF plays an important role
in the development of protective immunity against L. major
in vivo. Furthermore, they indicate that the susceptibility of
MIF
/
mice to L. major infection is due to
impaired macrophage leishmanicidal activity rather than dysregulation
of Th1 and Th2 responses.
 |
INTRODUCTION |
Most inbred mice are resistant to
cutaneous Leishmania major infection and develop small
self-resolving lesions (1, 16). It is widely accepted that
the ability of genetically resistant mice to resolve cutaneous L. major infection is associated with the development of
interleukin-12 (IL-12)-induced Th1 response and gamma interferon
(IFN-
) production. The protective role of IFN-
has been
attributed to its ability to induce the Th1 response, inhibit Th2
differentiation, and enhance macrophage leishmanicidal activity
(16).
Migration-inhibitory factor (MIF) is a pleiotropic cytokine that is
produced by many cells, including macrophages, T cells, and the
pituitary gland, during inflammatory responses. MIF inhibits anti-inflammatory effects of corticosteroids and plays a critical role
in pathogenesis of sepsis (3, 4). Additionally, MIF also
acts as an enzyme and catalyzes the tautomerization of several substrates (21). Experimental studies using
MIF-neutralizing antibodies indicate that this cytokine is involved in
pathogenesis of autoimmune diseases such as collagen type II-induced
arthritis and immunologically induced kidney disease (11,
14). Recent studies show that MIF counteracts the antitumor
activity of p53 and appears to link chronic inflammation and tumor
formation (9).
Studies from our laboratory and others indicate that MIF may play a
critical role in regulation of host immunity or susceptibility to
pathogens. For example, we found that MIF
/
mice cleared
gram-negative Pseudomonas aeruginosa bacteria more efficiently than MIF+/+ mice, indicating that MIF is
involved in pathogenesis of pulmonary P. aeruginosa
infection (4). In contrast, oral administration of MIF
alone or together with tumor necrosis factor alpha (TNF-
) via
transfected attenuated Salmonella enterica serovar
Typhimurium enhanced resistance of BALB/c mice to L. major
(23). Furthermore, others demonstrated that MIF with
endogenous TNF-
enhances macrophage NO production and induces in
vitro killing of L. major by macrophages (10).
Interestingly, the same study found that both susceptible BALB/c and
resistant C57BL/6 mice express high levels of MIF mRNA in their
draining lymph nodes following L. major infection
(10). Therefore, we examined the cutaneous growth of
L. major infection in MIF gene-deficient C57BL/6 × 129/Sv (MIF
/
) mice and compared it with growth in
similarly infected age and sex-matched wild-type (MIF+/+)
mice. In addition, we analyzed the leishmanicidal activity of resident
macrophages and measured cytokine production by the draining lymph nodes from L. major-infected MIF+/+
and MIF
/
mice. Our results indicate that MIF plays a
critical role in the development of protective immunity and
control of cutaneous L. major infection.
 |
MATERIALS AND METHODS |
Mice.
MIF gene-deficient C57BL/6 × 129/Sv mice were
generated by gene targeting as described previously (4).
MIF
/
mice were maintained by mating between homozygous
mice on the C57BL/6 × 129Sv background. The wild-type littermates
were used to generate wild-type MIF+/+ mice of the same age
and sex that were used as controls in all experiments. Mice were
maintained in the specific-pathogen-free facility at the Harvard School
of Public Health according to the guidelines for animal research.
Parasites.
L. major LV39 was maintained by serial
passage of parasites in BALB/c mice. Amastigotes isolated from lesions
of infected BALB/c mice were grown to stationary phase as described
previously (18).
Infection protocol and quantitation of parasite burdens.
Mice 8 to 12 weeks old were injected in the hind footpad with 2 × 106 stationary-phase promastigotes enumerated using a
Nuebauer hemacytometer. Lesion growth was monitored by measuring the
increase in thickness of the infected footpad using a dial-gauge
micrometer (18) at weekly intervals up to 12 weeks after
infection and comparing this to the thickness of the contralateral
uninfected footpad.
Parasite burdens in the infected footpads were determined by
limiting-dilution analysis, as described previously (18).
IL-12 treatment.
Recombinant murine IL-12 (R & D Systems
Inc.) was used to treat MIF
/
mice in doses described
previously (22). Briefly, 1 µg of IL-12 in 100 µl was
administered intraperitoneally to each MIF
/
mouse 1 day
prior to L. major infection, followed by a daily dose of 1 µg/per mouse for 5 days thereafter. Control MIF
/
mice
received injections of 100 µl of sterile phosphate-buffered saline (PBS).
T-cell proliferation and cytokine assays.
T-cell
proliferation was determined as previously described (20).
MIF+/+ and MIF
/
mice were sacrificed on
weeks 2, 6, and 12 following L. major infection. The
inguinal lymph nodes were removed and teased gently to prepare a
single-cell suspension. Briefly, 3 × 105 cells were
added in triplicate to the wells of sterile 96-well flat-bottomed
tissue culture plates (Costar, Cambridge, Mass.) and stimulated with
Leishmania antigen (LmAg; 20 µg/ml). Supernatants were
collected after 72 h of incubation and analyzed for the production of IL-4 (reagent purchased from Endogen, Cambridge, Mass.; detection limit, 10 pg/ml) and IFN-
(both reagents purchased from PharMingen, San Diego, Calif.; detection limit, 20 pg/ml) by capture enzyme-linked immunosorbent assay (ELISA) (20). Similarly, supernatants
from macrophage cultures were also analyzed for IL-6, IL-10, IL-12, and
TNF-
production by ELISA.
Assessment of macrophage leishmanicidal activity.
Resting
peritoneal macrophages were added to the wells of 24-well flat-bottomed
plates containing 12-mm-diameter glass coverslips. Cells were incubated
at 37°C for 4 h to allow macrophages to adhere to the
coverslips. Nonadherent cells were removed by gentle washing, and
adherent macrophages were infected with L. major
promastigotes (parasite/macrophage ratio, 5:1) for 4 h, washed,
and cultured in the presence of 200 U of IFN-
(Genzyme, Cambridge,
Mass.) per ml for 72 h. At this time, macrophages were stained by
Giemsa stain, and coverslips were mounted upside down on a glass slide; intracellular amastigotes were counted by microscopy.
Assessment of NO2
and
O2
production.
The supernatants from the
above assays were analyzed for nitrite concentration using Griess
reagent as described previously (6). For determining
levels of O2
, IFN-
-treated macrophages
were stimulated with phorbol myristate acetate, and superoxide
dismutase-inhibitable reduction of Fe3+
cytochrome c to the ferrous form
(Fe2+) was measured. The amount of
O2
released was calculated as described
previously (15).
Statistical significance.
Student's unpaired t
test was used to determine the statistical significance of values.
 |
RESULTS AND DISCUSSION |
We have previously demonstrated that oral administration of MIF
alone or together with IFN-
and TNF-
via transfected attenuated Salmonella cells conferred significant protection against
L. major infection in susceptible BALB/c mice
(23). Moreover, others found that MIF enhanced in vitro
macrophage leishmanicidal activity (10). In the present
study, following infection with 2 × 106 L. major stationary-phase promastigotes, MIF+/+ mice
developed lesions that resolved spontaneously by week 12 postinfection
(Fig. 1A). In contrast, similarly
infected MIF
/
mice displayed smaller lesions than
MIF+/+ mice in the early phase of infection but developed
large lesions which failed to resolve as infection progressed (Fig.
1A). Concomitantly infected BALB/c mice developed large, rapidly
progressive ulcerating lesions by week 6 postinfection (data not
shown). At week 12 postinfection, infected footpads from
MIF
/
mice also contained significantly more parasites
(>100-fold) than those from MIF+/+ mice (Fig. 1B). Taken
together, these findings indicate that endogenous MIF plays an
important role in the development of protective immunity against
L. major in resistant C57BL/6 × 129Sv/Ev mice.

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 1.
MIF / mice are relatively more
susceptible to cutaneous L. major infection than
MIF+/+ mice and develop large lesions. (A) Course of
cutaneous L. major infection in MIF / (solid
squares) and MIF+/+ (open squares) mice following infection
with 2 × 106 stationary-phase promastigotes. Disease
progression was monitored by measuring the increase in thickness of the
infected footpad and comparing this to the thickness of the
contralateral uninfected footpad. (B) Footpad parasite burdens in
MIF / and MIF+/+ mice were determined at
week 12 postinfection by limiting-dilution analysis. Data are expressed
as the mean titer ± the standard error (SE). Similar results were
observed in three and two independent experiments (A and B,
respectively).
|
|
Several studies have demonstrated that control of L. major
infection in resistant mice is associated with the development of the
IL-12-mediated Th1-like response and the production of IFN-
, whereas
susceptibility to L. major infection is associated with
development of a Th2-like response and the production of IL-4 (8,
13, 19). A previous study had demonstrated that MIF plays a
critical regulatory role in the activation of T cells (2).
Furthermore, MIF was produced by the Leishmania-specific Th2
clone (D10G4.1, L1/1), but not the Th1 (LNC2, B10/B1) clone following
in vitro stimulation with mitogen (2). Therefore, we
compared IL-4 and IFN-
production by LmAg-stimulated lymph node
cells from L. major-infected MIF
/
and
MIF+/+ mice at weeks 2, 6, and 12 postinfection to
determine whether susceptibility of MIF
/
mice to
L. major is due to an enhanced Th2-like response and/or an
impaired Th1-like response. We also measured serum levels of LmAg-specific Th1-associated immunoglobulin G2a (IgG2a) and
Th2-associated IgG1 antibodies. Following in vitro stimulation with
LmAg, lymph node cells from both L. major-infected
MIF
/
and MIF+/+ mice displayed significant
but similar levels of proliferative responses (data not shown) and
produced significant amounts of IFN-
and IL-4. Levels of IFN-
and
IL-4 in lymph node cell culture supernatants from MIF
/
mice were either higher or similar to those from MIF+/+
mice, although the differences were not statistically significant (Fig.
2A and B). At week 12 postinfection,
MIF+/+ and MIF
/
mice displayed comparable
titers of IgG1 (34,400 ± 23,200 and 46,050 ± 14,927 in
MIF+/+ and MIF
/
mice, respectively; P < 0.375) and IgG2a (19,200 ± 12,255 and 43,328 ± 17,952 in MIF+/+ and MIF
/
mice,
respectively; P < 0.1). Moreover, in one experiment,
although administration of recombinant murine IL-12 to
MIF
/
mice significantly inhibited lesion growth in the
early course of L. major infection between 3 and 6 weeks,
these mice eventually developed large lesions comparable to those of
control MIF
/
mice treated with PBS (Fig.
3). Although lesion sizes in
IL-12-treated MIF
/
mice were smaller than in
PBS-treated MIF
/
mice at weeks 7 and 8 postinfection
these differences were statistically not significant. As previous
studies have clearly demonstrated that IL-12 induces production of
IFN-
from NK cells and T cells, it is most likely that enhanced
resistance of IL-12-treated MIF
/
mice against L. major in the early course of infection is due to an increase in
IFN-
production. Nevertheless, taken together, these observations
suggest that endogenous MIF may not be involved in the regulation of
T-cell activation and production of cytokines IL-4 and IFN-
following L. major infection.

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 2.
Kinetics of in vitro cytokine production by
LmAg-stimulated lymph node cells from MIF / (solid
squares) and MIF+/+ (open squares) mice. (A) IFN- and
(B) IL-4 production by draining lymph node cells following in vitro
stimulation with LmAg (20 µg/ml) was measured at weeks 2, 6, and 12 postinfection by ELISA. The graph shows the mean (n = 6 to 9 animals) of two separate experiment. Data are expressed as the
mean ± SE.
|
|

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 3.
Effect of recombinant IL-12 treatment on course of
L. major infection in MIF / mice. Disease
progression was monitored by measuring the increase in the thickness of
infected footpad and comparing this to the thickness of the
contralateral uninfected footpad. Data are expressed as mean increase
in footpad thickness ± SE. Four mice were used in each group.
|
|
Macrophages activated by the cytokines IFN-
and TNF-
are major
effector cells involved in killing of Leishmania
(12). The leishmanicidal activity of cytokine-activated
macrophages has been attributed to their ability to produce
microbicidal effector molecules such as nitric oxide and superoxide
(12). MIF has been shown to induce TNF-
and NO
production in human monocytes (5) and activate murine
macrophages to kill Leishmania major in vitro
(10). Furthermore, we previously demonstrated that susceptible BALB/c mice that were orally administered MIF together with
IFN-
and TNF-
via transfected attenuated Salmonella
express markedly higher levels of nitric oxide synthase 2 in their
lymph nodes and developed significantly smaller lesions than control animals (23). Together, these findings indicate that the
protective role of MIF in murine leishmaniasis can be attributed to its
ability to induce macrophage leishmanicidal activity by increasing NO production.
To determine whether the susceptibility of MIF
/
mice to
L. major can be attributed to macrophage dysfunction, we
compared the ability of resting peritoneal macrophages from
MIF
/
and MIF+/+ mice to produce
proinflammatory cytokines and kill L. major promastigotes following in vitro stimulation with IFN-
. Four hours after infection with L. major promastigotes, macrophages from
MIF
/
and MIF+/+ mice displayed similar
parasite loads (116 ± 13 and 110 ± 18 parasites/200
macrophages in MIF+/+ and MIF
/
macrophages,
respectively; P < 0.4), indicating that initial uptake
of parasites is not increased in MIF
/
macrophages.
After 72 h, IFN-
induced significant parasite killing in
macrophages from both MIF
/
and MIF+/+ mice
compared to control macrophages that were not stimulated with IFN-
(Fig. 4A). At this time point, however,
IFN-
-stimulated macrophages from MIF
/
mice displayed
significant impairment of leishmanicidal activity compared to
MIF+/+ mice (Fig. 4B and C). Furthermore, impairment of the
in vitro leishmanicidal activity of MIF
/
macrophages
was associated with significantly lower production of superoxide (two-
to threefold) and nitric oxide (fivefold) than MIF+/+
macrophages (Fig. 5A and B). There were
no significant differences in the levels of IL-10, transforming growth
factor beta (TGF-
), and IL-12 in culture supernatants from
MIF+/+ and MIF
/
mice (data not shown).
Interestingly, macrophages from MIF
/
mice produced
significantly more IL-6 than those from MIF+/+ mice (Fig.
6). In contrast, culture supernatants
from LmAg-stimulated lymph node cells from MIF+/+ and
MIF
/
mice contained only basal levels of IL-6,
suggesting that MIF
/
T cells do not overproduce IL-6.
Several studies indicate that IL-6 is a proinflammatory cytokine;
others, however, have reported that it can also exhibit
immunosuppressive activity and induce differentiation of IL-4-producing
CD4+ T cells (17). In fact, IL-6 has been
shown to suppress superoxide production in human monocytes and to
inhibit their leishmanicidal activity in vitro (7).

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 4.
Resting peritoneal macrophages from MIF /
mice display impairment of IFN- -induced leishmanicidal activity.
Macrophages were infected with L. major stationary-phase
promastigotes as described in Materials and Methods and stimulated with
200 U of IFN- per ml for 72 h. The number of amastigotes per
200 infected macrophages (A and B) and the percentage of infected
macrophages (C) were determined microscopically by Giemsa staining.
This experiment is representative of two performed. Four to five mice
were used in each group, and cells were plated in triplicate.
|
|

View larger version (12K):
[in this window]
[in a new window]
|
FIG. 5.
Production of nitric oxide (NO) and superoxide
(O2 ) is impaired in macrophages from
MIF / mice. (A) Nitric oxide production and (B)
superoxide (O2 ) production were measured as
described in Materials and Methods. Similar results were observed in
two independent experiments. Data are expressed as mean ± SE.
|
|

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 6.
Macrophages from MIF / mice (open
squares) produce significantly more IL-6 than those from
MIF+/+ mice (squares). Resting peritoneal macrophages were
infected with L. major promastigotes in vitro and stimulated
with IFN- (200 U/ml). IL-6 production was measured at 12, 24, and
48 h postinfection by ELISA. Data are expressed as the mean of
triplicates ± SE. Similar results were observed in three
independent experiments.
|
|
In our previous paper (4), we reported that
thioglycolate-induced macrophages from MIF
/
mice
produced the same amount of IL-6 as and a little more NO than wild-type
mice. These differences from the present findings are probably due to
the much greater stimulus of macrophages used in the earlier study;
macrophages induced by thioglycolate may be more activated than
resident macrophages. These cells were further stimulated with both
lipopolysaccharide (LPS) and IFN-
rather than with IFN-
alone, as
in the present studies. Therefore, it is perhaps not surprising that
thioglycolate-elicited and IFN-
/LPS-activated peritoneal macrophages
from MIF
/
mice killed Leishmania as
efficiently as MIF+/+ macrophages (26% ± 10% and 33% ± 11% infected macrophages in MIF+/+ and
MIF
/
mice, respectively; P < 0.4). The
present protocol using resident macrophages and stimulation with
IFN-
alone is probably more closely related to the physiological reality.
There may be several explanations why IFN-
-activated
MIF
/
macrophage have impaired leishmanicidal activity.
First, increased IL-6 production may contribute at least partly to
increased susceptibility of MIF
/
mice to L. major by inhibiting macrophage superoxide production, as reported
previously (7). Hence, we are currently generating IL-6/MIF double-knockout mice to investigate this further. Second, as
MIF has been shown to induce TNF-
, impaired leishmanicidal activity
of resident peritoneal macrophages from MIF
/
mice may
be due to reduced TNF-
production. This, however, is unlikely in the
present study, as TNF-
was either absent or detectable only at basal
levels in culture supernatants from both groups (data not shown).
Lastly, it is possible that lack of MIF suppresses expression of
IFN-
and/or TNF receptors on macrophages that are essential for
mediating the biological functions of these cytokines. We are presently
investigating this hypothesis in studies in our laboratory.
Nevertheless, together these results indicate that the protective role
of endogenous MIF against L. major in resistant mice is
mediated by its ability to regulate superoxide and NO production and
induce macrophage leishmanicidal activity.
In conclusion, our findings in the present study demonstrate that MIF
gene-deficient C57BL/6 × 129Sv/Ev mice are susceptible to
cutaneous L. major infection and develop larger lesions and greater parasite burdens than their wild-type counterparts. The susceptibility of MIF
/
mice to L. major is
due to impaired IFN-
-induced macrophage leishmanicidal activity
rather than to the lack of Th1 development or enhanced Th2 development.
These observations indicate that endogenous MIF is required for optimal
activation of macrophages and control of L. major infection
in resistant mice. Additionally, the data demonstrate that MIF is not
required for activation of T cells and production of Th1-associated
IFN-
and Th2-associated IL-4.
 |
ACKNOWLEDGMENT |
This work was funded in part by National Institutes of Health
grant AI22532-13.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Dept. of
Immunology and Infectious Diseases, Harvard School of Public Health,
Bldg. 1, Rm. 804, 665 Huntington Avenue, Boston, MA 02115. Phone: (617) 432-4884. Fax: (617) 738-4914. E-mail:
asatoska{at}hsph.harvard.edu.
Editor:
R. N. Moore
 |
REFERENCES |
| 1.
|
Alexander, J.,
A. R. Satoskar, and D. G. Russell.
1999.
Leishmania species: models of intracellular parasitism.
J. Cell Sci.
112:2993-3002[Abstract].
|
| 2.
|
Bacher, M.,
C. Metz,
T. Calandra,
K. Mayer,
J. Chesney,
M. Lhoff,
D. Gemsa,
T. Donnelly, and R. Bucala.
1996.
An essential role for MIF in T cell activation.
Proc. Natl. Acad. Sci. USA
93:7849-7854[Abstract/Free Full Text].
|
| 3.
|
Bernhagen, J.,
T. Calandra,
R. A. Mitchell,
S. B. Martin,
K. J. Tracey,
W. Voelter,
K. R. Manouge,
A. Cerami, and R. Bucala.
1993.
MIF is a pituitary-derived cytokine that potentiates lethal endotoxemia.
Nature
365:756-759[CrossRef][Medline].
|
| 4.
|
Bozza, M.,
A. R. Satoskar,
G. Lin,
B. Lu,
A. A. Humbles,
C. Gerard, and J. R. David.
1999.
Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis.
J. Exp. Med.
189:341-346[Abstract/Free Full Text].
|
| 5.
|
Calandra, T.,
J. Bernhagen,
R. A. Mitchell, and R. Bucala.
1994.
The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor.
J. Exp. Med.
179:1895-1902[Abstract/Free Full Text].
|
| 6.
|
Green, L. C.,
D. A. Wagner,
J. Glogowski,
P. L. Skipper,
J. S. Wishnok, and S. R. Tannenbaum.
1982.
Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids.
Anal. Biochem.
126:131-138[CrossRef][Medline].
|
| 7.
|
Hatzigeorgiou, D. E.,
S. He,
J. Sobel,
K. H. Grabstein,
A. Hafner, and J. L. Ho.
1993.
IL-6 down-modulates the cytokine-enhanced antileishmanial activity in human macrophages.
J. Immunol.
151:3682-3692[Abstract].
|
| 8.
|
Heinzel, F. P.,
M. D. Sadick,
S. S. Mutha, and R. M. Locksley.
1991.
Production of interferon- , interleukin2, interleukin 4, and interleukin 10 by CD4+ T lymphocytes in vivo during healing and progressive murine leishmaniasis.
Proc. Natl. Acad. Sci. USA
88:7011-7015[Abstract/Free Full Text].
|
| 9.
|
Hudson, J. D.,
M. A. Shoaibi,
R. Maestro,
A. Carnero,
G. J. Hannon, and D. H. Beach.
1999.
A proinflammatory cytokine inhibits p53 tumor suppressor activity.
J. Exp. Med.
190:1375-1382[Abstract/Free Full Text].
|
| 10.
|
Juttner, S.,
J. Bernhagen,
C. N. Metz,
M. Rollinghoff,
R. Bucala, and A. Gessner.
1998.
Migration inhibitory factor induces killing of Leishmania major by macrophages: dependent on reactive nitrogen intermediates and endogenous TNF- .
J. Immunol.
161:2383-2390[Abstract/Free Full Text].
|
| 11.
|
Lan, H.,
M. Bacher,
N. Yang,
W. Mu,
D. Nikolic-Paterson,
C. Metz,
A. Meinhardt,
R. Bucala, and R. Atkins.
1997.
The pathogenic role of macrophage migration inhibitory factor in immunologically induced kidney disease in the rat.
J. Exp. Med.
185:1455-1465[Abstract/Free Full Text].
|
| 12.
|
Liew, F. Y., and C. A. O'Donnell.
1993.
Immunology of leishmaniasis.
Adv. Parasitol.
32:161-259[Medline].
|
| 13.
|
Locksley, R. M.,
F. P. Heinzel,
B. J. Holaday,
S. S. Mutha,
S. L. Reiner, and M. D. Sadick.
1991.
Induction of Th1 and Th2 CD4+ subsets during murine Leishmania major infection.
Res. Immunol.
142:28-38[CrossRef][Medline].
|
| 14.
|
Mikulowska, A.,
C. Metz,
R. Bucala, and R. Holmdahl.
1997.
Macrophage migration inhibitory factor is involved in the pathogenesis of collagen type-II-induced arthritis in mice.
J. Immunol.
158:5514-5517[Abstract].
|
| 15.
|
Pick, E., and D. Mizel.
1981.
Rapid microassays for the measurement of superoxide and hydrogen peroxide production by macrophages in culture using an automatic enzyme imunoassay reader.
J. Immunol. Methods
46:211-226[CrossRef][Medline].
|
| 16.
|
Reed, S. G., and P. Scott.
1993.
T-cell and cytokine responses in leishmaniasis.
Curr. Opin. Immunol.
5:524-531[CrossRef][Medline].
|
| 17.
|
Rincon, M.,
J. Anguita,
T. Nakamura,
E. Fikrig, and R. A. Flavell.
1997.
IL-6 directs the differentiation of IL-4-producing CD4+ T cells.
J. Exp. Med.
185:461-469[Abstract/Free Full Text].
|
| 18.
|
Satoskar, A. R.,
L. M. Stamm,
X. Zhang,
A. A. Satoskar,
M. Okano,
C. Terhorst,
J. R. David, and B. Wang.
1999.
Mice lacking NK cells develop an efficient Th1 response and control cutaneous Leishmania major infection.
J. Immunol.
162:6747-6754[Abstract/Free Full Text].
|
| 19.
|
Scott, P.,
P. Natovitz,
R. L. Coffman,
E. Pearce, and A. Sher.
1988.
Immunoregulation of cutaneous leishmaniasis: T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens.
J. Exp. Med.
168:1675-1684[Abstract/Free Full Text].
|
| 20.
|
Stamm, L. M.,
A. Raisenen-Sokolowski,
M. Okano,
M. E. Russell,
J. R. David, and A. R. Satoskar.
1998.
Mice with STAT6-targeted gene disruption develop a Th1 response and control cutaneous leishmaniasis.
J. Immunol.
161:6180-6188[Abstract/Free Full Text].
|
| 21.
|
Swope, M. D., and E. Lolis.
1999.
Macrophage migration inhibitory factor: cytokine, hormone, or enzyme?
Rev. Physiol. Biochem. Pharmacol.
139:1-32[Medline].
|
| 22.
|
Sypek, J. P.,
C. L. Chung,
S. E. H. Mayor,
J. M. Subramanyam,
S. J. Goldman,
D. S. Sieburth,
S. F. Wolf, and R. G. Schaub.
1993.
Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response.
J. Exp. Med.
177:1797-1802[Abstract/Free Full Text].
|
| 23.
|
Xu, D.,
S. McSorley,
L. Tetley,
S. Chatfield,
G. Dougan,
W. Chan,
A. Satoskar,
J. R. David, and F. Y. Liew.
1998.
Protective effect on Leishmania major infection of migration inhibitory factor, TNF-alpha, and IFN-gamma administered orally via attenuated Salmonella typhimurium.
J. Immunol.
160:1285-1289[Abstract/Free Full Text].
|
Infection and Immunity, February 2001, p. 906-911, Vol. 69, No. 2
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.2.906-911.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Flores, M., Saavedra, R., Bautista, R., Viedma, R., Tenorio, E. P., Leng, L., Sanchez, Y., Juarez, I., Satoskar, A. A., Shenoy, A. S., Terrazas, L. I., Bucala, R., Barbi, J., Satoskar, A. R., Rodriguez-Sosa, M.
(2008). Macrophage migration inhibitory factor (MIF) is critical for the host resistance against Toxoplasma gondii. FASEB J.
22: 3661-3671
[Abstract]
[Full Text]
-
Murray, H. W.
(2008). Accelerated Control of Visceral Leishmania donovani Infection in Interleukin-6-Deficient Mice. Infect. Immun.
76: 4088-4091
[Abstract]
[Full Text]
-
Gore, Y., Starlets, D., Maharshak, N., Becker-Herman, S., Kaneyuki, U., Leng, L., Bucala, R., Shachar, I.
(2008). Macrophage Migration Inhibitory Factor Induces B Cell Survival by Activation of a CD74-CD44 Receptor Complex. J. Biol. Chem.
283: 2784-2792
[Abstract]
[Full Text]
-
Cho, Y., Jones, B. F., Vermeire, J. J., Leng, L., DiFedele, L., Harrison, L. M., Xiong, H., Kwong, Y.-K. A., Chen, Y., Bucala, R., Lolis, E., Cappello, M.
(2007). Structural and Functional Characterization of a Secreted Hookworm Macrophage Migration Inhibitory Factor (MIF) That Interacts with the Human MIF Receptor CD74. J. Biol. Chem.
282: 23447-23456
[Abstract]
[Full Text]
-
Augustijn, K. D., Kleemann, R., Thompson, J., Kooistra, T., Crawford, C. E., Reece, S. E., Pain, A., Siebum, A. H. G., Janse, C. J., Waters, A. P
(2007). Functional Characterization of the Plasmodium falciparum and P. berghei Homologues of Macrophage Migration Inhibitory Factor. Infect. Immun.
75: 1116-1128
[Abstract]
[Full Text]
-
Awandare, G. A., Ouma, Y., Ouma, C., Were, T., Otieno, R., Keller, C. C., Davenport, G. C., Hittner, J. B., Vulule, J., Ferrell, R., Ong'echa, J. M., Perkins, D. J.
(2007). Role of Monocyte-Acquired Hemozoin in Suppression of Macrophage Migration Inhibitory Factor in Children with Severe Malarial Anemia. Infect. Immun.
75: 201-210
[Abstract]
[Full Text]
-
Hoi, A. Y., Hickey, M. J., Hall, P., Yamana, J., O'Sullivan, K. M., Santos, L. L., James, W. G., Kitching, A. R., Morand, E. F.
(2006). Macrophage Migration Inhibitory Factor Deficiency Attenuates Macrophage Recruitment, Glomerulonephritis, and Lethality in MRL/lpr Mice. J. Immunol.
177: 5687-5696
[Abstract]
[Full Text]
-
Toh, M.-L., Aeberli, D., Lacey, D., Yang, Y., Santos, L. L., Clarkson, M., Sharma, L., Clyne, C., Morand, E. F.
(2006). Regulation of IL-1 and TNF Receptor Expression and Function by Endogenous Macrophage Migration Inhibitory Factor. J. Immunol.
177: 4818-4825
[Abstract]
[Full Text]
-
Aeberli, D., Leech, M., Morand, E. F.
(2006). Macrophage migration inhibitory factor and glucocorticoid sensitivity. Rheumatology (Oxford)
45: 937-943
[Abstract]
[Full Text]
-
Reyes, J. L., Terrazas, L. I., Espinoza, B., Cruz-Robles, D., Soto, V., Rivera-Montoya, I., Gomez-Garcia, L., Snider, H., Satoskar, A. R., Rodriguez-Sosa, M.
(2006). Macrophage Migration Inhibitory Factor Contributes to Host Defense against Acute Trypanosoma cruzi Infection.. Infect. Immun.
74: 3170-3179
[Abstract]
[Full Text]
-
Hardman, M. J., Waite, A., Zeef, L., Burow, M., Nakayama, T., Ashcroft, G. S.
(2005). Macrophage Migration Inhibitory Factor: A Central Regulator of Wound Healing. Am. J. Pathol.
167: 1561-1574
[Abstract]
[Full Text]
-
Oddo, M., Calandra, T., Bucala, R., Meylan, P. R. A.
(2005). Macrophage Migration Inhibitory Factor Reduces the Growth of Virulent Mycobacterium tuberculosis in Human Macrophages. Infect. Immun.
73: 3783-3786
[Abstract]
[Full Text]
-
Kar, S., Metz, C., McMahon-Pratt, D.
(2005). CD4+ T Cells Play a Dominant Role in Protection against New World Leishmaniasis Induced by Vaccination with the P-4 Amastigote Antigen. Infect. Immun.
73: 3823-3827
[Abstract]
[Full Text]
-
Riedemann, N. C., Guo, R.-F., Gao, H., Sun, L., Hoesel, M., Hollmann, T. J., Wetsel, R. A., Zetoune, F. S., Ward, P. A.
(2004). Regulatory Role of C5a on Macrophage Migration Inhibitory Factor Release from Neutrophils. J. Immunol.
173: 1355-1359
[Abstract]
[Full Text]
-
Wang, N., Satoskar, A., Faubion, W., Howie, D., Okamoto, S., Feske, S., Gullo, C., Clarke, K., Sosa, M. R., Sharpe, A. H., Terhorst, C.
(2004). The Cell Surface Receptor SLAM Controls T Cell and Macrophage Functions. JEM
199: 1255-1264
[Abstract]
[Full Text]
-
Leng, L., Metz, C. N., Fang, Y., Xu, J., Donnelly, S., Baugh, J., Delohery, T., Chen, Y., Mitchell, R. A., Bucala, R.
(2003). MIF Signal Transduction Initiated by Binding to CD74. JEM
197: 1467-1476
[Abstract]
[Full Text]
-
Muraille, E., De Trez, C., Brait, M., De Baetselier, P., Leo, O., Carlier, Y.
(2003). Genetically Resistant Mice Lacking MyD88-Adapter Protein Display a High Susceptibility to Leishmania major Infection Associated with a Polarized Th2 Response. J. Immunol.
170: 4237-4241
[Abstract]
[Full Text]
-
Nguyen, M. T., Lue, H., Kleemann, R., Thiele, M., Tolle, G., Finkelmeier, D., Wagner, E., Braun, A., Bernhagen, J.
(2003). The Cytokine Macrophage Migration Inhibitory Factor Reduces Pro-Oxidative Stress-Induced Apoptosis. J. Immunol.
170: 3337-3347
[Abstract]
[Full Text]
-
Rodriguez-Sosa, M., Rosas, L. E., David, J. R., Bojalil, R., Satoskar, A. R., Terrazas, L. I.
(2003). Macrophage Migration Inhibitory Factor Plays a Critical Role in Mediating Protection against the Helminth Parasite Taenia crassiceps. Infect. Immun.
71: 1247-1254
[Abstract]
[Full Text]
-
Koebernick, H., Grode, L., David, J. R., Rohde, W., Rolph, M. S., Mittrucker, H.-W., Kaufmann, S. H. E.
(2002). Macrophage migration inhibitory factor (MIF) plays a pivotal role in immunity against Salmonella typhimurium. Proc. Natl. Acad. Sci. USA
99: 13681-13686
[Abstract]
[Full Text]